Pregnancy introduces specific considerations for the ongoing management of genital lichen sclerosus in female patients. Choosing and applying maintenance therapy requires a pregnancy-aware approach distinct from standard out-of-pregnancy practice.
This protocol addresses female patients with genital lichen sclerosus who are pregnant. The presence of pregnancy shapes which topical agents are considered appropriate and how maintenance therapy is structured, with agent selection guided by safety in the context of gestation.
Maintenance therapy in this setting involves a potent topical corticosteroid, applied at the minimum frequency needed to keep the disease under control. Pregnancy specifically influences which agent within this class is preferred — the complete protocol details the preferred option and the approach to ongoing management.
We recommend maintenance treatment during pregnancy, consisting of a potent topical corticosteroids, such as mometasone furoate, with the minimum frequency needed to control the disease.
There is no objection to occasional use of topical corticosteroids in genital LS (e.g., once or twice a week); however, potent topical corticosteroids (e.g., mometasone furoate) are preferred to very potent topical corticosteroids (clobetasol propionate) during pregnancy.
View source ↗